FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W345985433> ?p ?o ?g. }

• W345985433 endingPage "328" @default.
• W345985433 startingPage "323" @default.
• W345985433 abstract "Immune thrombocytopenia (ITP) is an immune-mediated disease characterized by transient or persistent decrease of the platelet count to less than 100x109/L. Although it is included in a benign disease group, bleeding complications may be mortal. With a better understanding of the pathophysiology of the disease, thrombopoietin receptor agonists, which came into use in recent years, seem to be an effective option in the treatment of resistant cases. This study aimed to retrospectively assess the efficacy, long-term safety, and tolerability of eltrombopag in Turkish patients with chronic ITP in the Aegean region of Turkey.Retrospective data of 40 patients with refractory ITP who were treated with eltrombopag in the Aegean region were examined and evaluated.The total rate of response was 87%, and the median duration of response defined as the number of the platelets being over 50x109/L was 19.5 (interquartile range: 5-60) days. In one patient, venous sinus thrombosis was observed with no other additional risk factors due to or related to thrombosis. Another patient with complete response and irregular follow-up for 12 months was lost due to sudden death as the result of probable acute myocardial infarction.Although the responses to eltrombopag were satisfactory, patients need to be monitored closely for overshooting platelet counts as well as thromboembolic events.Amaç: İmmün trombositopeni (İTP), trombositlerin immün aracılı yıkım ile kalıcı veya geçici olarak 100x109/L altında olduğu bir hastalıktır. Selim hematolojik hastalıklar içinde yer almasına rağmen kanama komplikasyonları ölümcül olabilir. Hastalığın patofizyolojisi daha iyi anlaşılması ile son yıllarda kullanıma giren trombopoetin reseptör agonistleri, dirençli hastaların tedavisinde etkili bir seçenek olarak görünmektedir. Gereç ve Yöntemler: Bu çalışmada Ege Bölgesi’nde refrakter İTP tanısı ile eltrombopag ile tedavi edilen 8 farklı merkezden 40 hastanın retrospektif verileri incelenmiş ve değerlendirilmiştir. Bulgular: Çalışmada toplam yanıt oranı %87 idi ve trombositlerin 50x109/L’nin üzerine çıktığı medyan süre 19,5 (5-60) gün saptandı. Tromboz için başka hiçbir ek risk faktörü bulunmayan bir hastada venöz sinüs trombozu gözlendi. On iki aydır tam yanıtlı izlenen ve düzensiz takibe gelen bir diğer hasta olası akut miyokard infarktüsü sonucu gelişen ani ölüm nedeni ile kaybedildi. Sonuç: Her ne kadar eltrombopag yanıtları tatmin edici olsa da, hızlı ilerleyen trombositemiye bağlı gelişecek tromboembolik olaylar açısından, yakın takip ve monitorizasyon gereklidir." @default.
• W345985433 created "2016-06-24" @default.
• W345985433 creator A5003718731 @default.
• W345985433 creator A5004836161 @default.
• W345985433 creator A5013426898 @default.
• W345985433 creator A5015660022 @default.
• W345985433 creator A5016899843 @default.
• W345985433 creator A5017186675 @default.
• W345985433 creator A5025935841 @default.
• W345985433 creator A5029708388 @default.
• W345985433 creator A5030718923 @default.
• W345985433 creator A5035931091 @default.
• W345985433 creator A5049882856 @default.
• W345985433 creator A5058912380 @default.
• W345985433 creator A5061704854 @default.
• W345985433 creator A5064328293 @default.
• W345985433 creator A5067702018 @default.
• W345985433 creator A5067742715 @default.
• W345985433 creator A5067769772 @default.
• W345985433 creator A5076821260 @default.
• W345985433 creator A5077709901 @default.
• W345985433 creator A5081664284 @default.
• W345985433 creator A5081916189 @default.
• W345985433 creator A5090217849 @default.
• W345985433 date "2015-12-05" @default.
• W345985433 modified "2023-10-18" @default.
• W345985433 title "Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience" @default.
• W345985433 cites W1531484155 @default.
• W345985433 cites W1574141134 @default.
• W345985433 cites W1966904697 @default.
• W345985433 cites W1966937027 @default.
• W345985433 cites W1984073642 @default.
• W345985433 cites W1991437102 @default.
• W345985433 cites W2054111587 @default.
• W345985433 cites W2058437162 @default.
• W345985433 cites W2059190713 @default.
• W345985433 cites W2073163222 @default.
• W345985433 cites W2075090852 @default.
• W345985433 cites W2109141325 @default.
• W345985433 cites W2131791915 @default.
• W345985433 cites W2156817733 @default.
• W345985433 cites W2157590902 @default.
• W345985433 cites W2167805334 @default.
• W345985433 cites W4229618832 @default.
• W345985433 doi "https://doi.org/10.4274/tjh.2014.0152" @default.
• W345985433 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4805331" @default.
• W345985433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25914025" @default.
• W345985433 hasPublicationYear "2015" @default.
• W345985433 type Work @default.
• W345985433 sameAs 345985433 @default.
• W345985433 citedByCount "7" @default.
• W345985433 countsByYear W3459854332016 @default.
• W345985433 countsByYear W3459854332018 @default.
• W345985433 countsByYear W3459854332021 @default.
• W345985433 countsByYear W3459854332022 @default.
• W345985433 crossrefType "journal-article" @default.
• W345985433 hasAuthorship W345985433A5003718731 @default.
• W345985433 hasAuthorship W345985433A5004836161 @default.
• W345985433 hasAuthorship W345985433A5013426898 @default.
• W345985433 hasAuthorship W345985433A5015660022 @default.
• W345985433 hasAuthorship W345985433A5016899843 @default.
• W345985433 hasAuthorship W345985433A5017186675 @default.
• W345985433 hasAuthorship W345985433A5025935841 @default.
• W345985433 hasAuthorship W345985433A5029708388 @default.
• W345985433 hasAuthorship W345985433A5030718923 @default.
• W345985433 hasAuthorship W345985433A5035931091 @default.
• W345985433 hasAuthorship W345985433A5049882856 @default.
• W345985433 hasAuthorship W345985433A5058912380 @default.
• W345985433 hasAuthorship W345985433A5061704854 @default.
• W345985433 hasAuthorship W345985433A5064328293 @default.
• W345985433 hasAuthorship W345985433A5067702018 @default.
• W345985433 hasAuthorship W345985433A5067742715 @default.
• W345985433 hasAuthorship W345985433A5067769772 @default.
• W345985433 hasAuthorship W345985433A5076821260 @default.
• W345985433 hasAuthorship W345985433A5077709901 @default.
• W345985433 hasAuthorship W345985433A5081664284 @default.
• W345985433 hasAuthorship W345985433A5081916189 @default.
• W345985433 hasAuthorship W345985433A5090217849 @default.
• W345985433 hasBestOaLocation W3459854331 @default.
• W345985433 hasConcept C109159458 @default.
• W345985433 hasConcept C119060515 @default.
• W345985433 hasConcept C121332964 @default.
• W345985433 hasConcept C126322002 @default.
• W345985433 hasConcept C141071460 @default.
• W345985433 hasConcept C142424586 @default.
• W345985433 hasConcept C197934379 @default.
• W345985433 hasConcept C2776915898 @default.
• W345985433 hasConcept C2777863708 @default.
• W345985433 hasConcept C2778375690 @default.
• W345985433 hasConcept C2779338263 @default.
• W345985433 hasConcept C2780588981 @default.
• W345985433 hasConcept C2780653079 @default.
• W345985433 hasConcept C2780868729 @default.
• W345985433 hasConcept C28328180 @default.
• W345985433 hasConcept C2993327898 @default.
• W345985433 hasConcept C54355233 @default.
• W345985433 hasConcept C71924100 @default.
• W345985433 hasConcept C86803240 @default.

• next